Severe but reversible neonatal neurological dysfunction associated with in utero exposure to Sibelium (flunarizine dihydrochloride

Article type: Research Article

Authors: Kilani, R.A.

Affiliations: Division of Neonatology, Department of Pediatrics, Istishari Hospital, Amman, Jordan

Note: [] Corresponding author: Dr. Ramzi A. Kilani, Division of Neonatology, NICU at Istishari Hospital, 42 Alkindi Street, Amman 11184, Jordan. Tel.: +962 797233375; E-mail: [email protected]

Abstract: Sibelium is a Ca++ channel blocker used as a prophylactic treatment of migraine. No published data exist on the effect of Sibelium on the human fetus during pregnancy or newborn infant following delivery. We report two female siblings who were exposed to Sibelium during fetal life. Both were born with severe neurological depression requiring mechanical ventilation for 5 and 7 days. The findings consisted of hypotonia, hypoventilation/apnea, absent spontaneous movements, absent neonatal reflexes, contractures and skin edema. All the neurological abnormalities reversed by 5 to 7 days. The use of Sibelium during pregnancy can be associated with significant and severe, but reversible, neurological manifestations. The long term effect on neurological development remains concerning but unknown.

Keywords: Ca channel blocker, neuroprotective, migraine

DOI: 10.3233/NPM-1262312

Journal: Journal of Neonatal-Perinatal Medicine, vol. 5, no. 4, pp. 389-392, 2012